Article Correctness Is Author's Responsibility: A novel pathway to target colorectal cancer

(Medical University of South Carolina) Survival rates for patients with late-stage colorectal cancer are dismal, and new therapeutic strategies are needed to improve outcomes. Prostaglandin E2 (PGE2) stimulates inflammation and is thought to promote colorectal tumor progression, but how it does so was not well understood. Medical University of South Carolina investigators report in Gastroenterology that PGE2 treatment of colorectal cancer cells promotes tumor formation and progression by increasing levels of a particular microRNA, revealing a potential new therapeutic target.